Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum

January 25, 2024

https://www.globenewswire.com/news-release/2024/01/25/2816570/37414/en/Panbela-Exceeds-50-Enrollment-for-Aspire-Trial-in-Pancreatic-Cancer-Exceeding-Anticipated-Timelines-with-Accelerated-Momentum.html

MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced it has reached 50% enrollment for its ASPIRE global clinical trial in the first-line treatment of metastatic pancreatic cancer. ASPIRE is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. Detailed information on the trial can be located at https://clinicaltrials.gov/ct2/show/NCT05254171 .

Read more at globenewswire.com

Related news for (PBLA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.